newsfilter
← Latest News
GlobeNewswire·

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

Site activation and screening for the Phase 3 RESTORE study is expected to begin in September 2026, with the first participant anticipated to be dosed shortly thereafter. Strengthened leadership team, appointing Keith